Matthew K. Abramowitz, M.D.
Matthew Abramowitz, MD, Assistant Professor of Medicine and Epidemiology & Population Health, is a recipient of a Career Development Award from the Institute of Clinical and Translational Research, the Einstein-Montefiore CTSA. His research
focuses on the association of metabolic acidosis with the progression of, and complications related to, chronic kidney disease.
Dr. Abramowitz is currently studying the association of acidosis with loss of muscle strength, bone disease, and insulin resistance, all causes of significant morbidity in individuals with chronic kidney disease. Future studies will examine the efficacy of alkali therapy in ameliorating these conditions and slowing the progression of kidney disease.
- Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonatelevels and the progression of kidney disease: a cohort study. Am J Kidney Dis.Aug;54(2):270-7, 2009.
- Bauer C, Abramowitz M, Hostetter TH. Is angiotensin systemblockade indicated in the elderly? Nat Rev Nephrol. Jan;6(1):11-2, 2010.
- Alencar C, Abramowitz M, Parekh S, Braunshweig I, Jacobson M,Silverman L, Verma A. Atypical presentations of Sweet's syndrome in patientswith MDS/AML receiving combinationsof hypomethylating agents with histone deacetylase inhibitors. Am J Hematol2009 Oct; 84(10):688-689
- Abramowitz M, Muntner P, Coco M, Southern W, Lotwin I, Hostetter TH, Melamed ML. Serum alkaline phosphatase and phosphate and risk of mortalityand hospitalization. (in revision â Clin J Am Soc Nephrol)
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.